[1] R. Siegel, E. Ward, O. Brawley, et al. A. Jemal Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J.Clin., 61 (2011), pp. 212-236
[2] Pujade-Lauraine E, Hilpert F, Weber, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA openlabel randomized phase III trial. J Clin Oncol. 2014;32:1302-8.10.1200
[3] Shoji T, Komiyama S, Kigawa J, et al. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023. BMC Cancer. 2018;18:771.10.1186
[4] Coburn SB, Bray F, Sherman ME, et.al. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140:2451-60.10.1002
[5] 婦⼈科腫瘍委員会報告 2017 年度患者年報：⽇産婦 2019;71：699-724
[6] Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284-96.10.3322
[7] Gurung A, Hung T, Morin J,et.al. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology. 2013;62:59- 70.10.1111
[8] 卵巣癌治療ガイドライン 2020 年度版：126-127 編集 ⽇本婦⼈科腫瘍学会 ⾦原出版
[9] Du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320-9.10.1093
[10] Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386:249-57.10.1016
[11] Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S161-192
[12] Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-393
[13] Markman M, Markman J, Webster K, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22:3120-5.10.1200
[14] Chan JK, Cheung MK, Husain A, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006;108:521-8.10.1097
[15] Bowtell DD, Böhm S, Ahmed AA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668- 79.10.1038
[16] Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496-504.10.1097
[17] Bast RC, Jr., Feeney M, Lazarus H, et al.Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331-7.10.1172
[18] Bast RC, Jr., Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-7.10.1056
[19] Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695-700
[20] Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75:264-5.10.1002
[21] Ferraro S, Braga F, Lanzoni M,.et al Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66:273-81.10.1136
[22] Markman M. The Role of CA-125 in the Management of Ovarian Cancer. Oncologist. 1997;2:6-9
[23] Hirsch M, Duffy J,Davis CJ,et al. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis. Bjog. 2016;123:1761- 8.10.1111
[24] Da Yang , Sofia Khan, Yan Sun, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011 Oct 12;306(14):1557-65: 10.1001
[25] NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995 Fe8;273:491-7.
[26] Harmandayan GZ, Gao F, Mutch DG, et al. Ovarian cancer patient surveillance after curative-intent initial treatment. Gynecol Oncol. 2011;120:205-8.10.1016
[27] Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996;7:361-4.10.1093
[28] Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71:164-74.10.1016
[29] Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104:863-70.10.1038
[30] Tokunaga H, Mikami M, Nagase S, et al. The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. J Gynecol Oncol. 2021;32:e49.10.3802
[31] Wilder JL, Pavlik E, Straughn JM, et al. Clinical implications of a rising serum CA125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol. 2003;89:233-5.10.101
[32] Santillan A, Garg R, Zahurak ML, et al. 2nd, Armstrong DK, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23:9338-43.10.1200
[33] Meier W, Baumgartner L, Stieber P, et al. CA125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Res. 1997;17:3019-20
[34] Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancergenetics in the blood. Nat Rev Clin Oncol. 2013;10:472-84.10.1038
[35] Mandel P, Metais P. Nuclear Acids In Human Blood Plasma. C R Seances Soc Biol Fil. 1948;142:241-3
[36] M Stroun , J Lyautey, C Lederrey, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release Clin Chim Acta. 2001 Nov;313(1-2):139-42. 10.1016
[37] Chetan Bettegowda , Mark Sausen, Rebecca J Leary, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24.10.1126
[38] Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223-38.10.1038
[39] Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985-90.10.1038
[40] Allegretti M, Cottone G, Carboni F, et al. Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy. J Exp Clin Cancer Res. 2020;39:69.10.1186
[41] Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015;90:509-15.10.1016
[42] William Pao , Nicolas Girard. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011 Feb;12(2):175-80.0.1016
[43] Asante DB, Calapre L, Ziman M, et al. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? Cancer Lett. 2020;468:59- 71.10.1016
[44] Pereira E, Camacho-Vanegas O, Anand S, et al. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers. PLoS One. 2015.10.1371
[45] Parkinson CA, Gale D, Piskorz AM, et al. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. PLoS Med. 201610.1371
[46] Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023-31.10.1038
[47] Sunami K, Ichikawa H, Kubo T, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 2019;110:1480-90.10.1111
[48] Shibuya Y, Tokunaga H, Saito S, et al. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. Genes Chromosomes Cancer. 2018.10.1002
[49] Ito S, Sato I, Mochizuki M, Minato T, et al. Robustness of a Cancer Profiling Test Using Formalin-fixed Paraffin Embedded Tumor Specimens. Anticancer Res. 2021;41:1341-8.10.21873
[50] Liu H, Bielinski SJ, Sohn S, et al. An information extraction framework for cohort identification using electronic health records. AMIA Jt Summits Transl Sci Proc. 2013;2013:149-53
[51] McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297-303.10.1101
[52] Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47:D941-d7.10.1093
[53] Wang K, Li M, Hakonarson H. ANNOVAR:functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.10.109
[54] Hinrichs AS, Karolchik D, Baertsch R, et al. The UCSC Genome Browser Database: update 2006. Nucleic Acids Res. 2006;34:D590-8.10.1093
[55] To EW, Chan KC, Leung SF, et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res. 2003;9:3254-9
[56] Network NCC. NCCN Clinical Practice Guidelines in Oncology: OvarianCancer. USA2017.
[57] Riedinger JM, Wafflart J, Ricolleau G, et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 2006;17:1234-8.10.1093
[58] Ebi H, Bando H. Precision Oncology and the Universal Health Coverage System in Japan. JCO Precis Oncol. 2019;3.10.1200
[59] Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548-54.10.1038
[60] N Tarazona , F Gimeno-Valiente , V Gambardella, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Annals of Oncology. 2019 Nov 1;30(11):1804-1812.
[61] Nakako S, Akemi S, Naomi K, et al. Correlation between plasma DNA and tumor status in an animal model. PLoS One. 2014 Dec 2;9(12):e111881. doi: 10.1371
[62] Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155-63.10.1016
[63]リキッドバイオプシーによるがん個別化医療の実現を⽬指す新プロジェクト 「CIRCULATE-Japan」 https://www.ncc.go.jp/jp/information/pr_release/2020/0610/index.html （閲覧⽇ 2022/1/20）
[64] ⾎液循環腫瘍 DNA 陰性の⾼リスク Stage II 及び低リスク Stage III 結腸癌治 癒切除例に対する術後補助化学療法としての CAPOX 療法と⼿術単独を⽐較するラ ンダム化第 III 相⽐較試験（VEGA trial） https://jrct.niph.go.jp/latest-detail/jRCT1031200006 （閲覧⽇ 2022/1/20）
論文の公開元へ
